Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1523592rdf:typepubmed:Citationlld:pubmed
pubmed-article:1523592lifeskim:mentionsumls-concept:C0042029lld:lifeskim
pubmed-article:1523592lifeskim:mentionsumls-concept:C0001792lld:lifeskim
pubmed-article:1523592lifeskim:mentionsumls-concept:C2349001lld:lifeskim
pubmed-article:1523592lifeskim:mentionsumls-concept:C0681850lld:lifeskim
pubmed-article:1523592lifeskim:mentionsumls-concept:C1706203lld:lifeskim
pubmed-article:1523592lifeskim:mentionsumls-concept:C2697811lld:lifeskim
pubmed-article:1523592lifeskim:mentionsumls-concept:C0226896lld:lifeskim
pubmed-article:1523592lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:1523592lifeskim:mentionsumls-concept:C0205531lld:lifeskim
pubmed-article:1523592lifeskim:mentionsumls-concept:C0205039lld:lifeskim
pubmed-article:1523592lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:1523592lifeskim:mentionsumls-concept:C1527415lld:lifeskim
pubmed-article:1523592lifeskim:mentionsumls-concept:C0028902lld:lifeskim
pubmed-article:1523592lifeskim:mentionsumls-concept:C1550501lld:lifeskim
pubmed-article:1523592lifeskim:mentionsumls-concept:C1521801lld:lifeskim
pubmed-article:1523592pubmed:issue1lld:pubmed
pubmed-article:1523592pubmed:dateCreated1992-10-15lld:pubmed
pubmed-article:1523592pubmed:abstractTextThe pharmacokinetics of ofloxacin orally administered were investigated at the steady-state in sixteen elderly patients older than 65 years. Patients with either urinary tract of respiratory tract mild infectious were divided into two age-dependent groups A and B. Group A: eight patients (65-80 years) received 200 mg of ofloxacin by the oral route every 12 hours and group B: eight patients older than 80 years, received 200 mg of ofloxacin by the oral route every 24 hours. The pharmacokinetic study was performed on treatment day 5. Plasmatic levels and urinary excretion of ofloxacin during 12 or 24 hours were assayed by means of high pressure liquid chromatography. Wide variations in plasma ofloxacin concentrations were observed within each group (Cmax range, group A: 1.9-9.2 mg/l, group B: 1.6-10.0 mg/l). Similar variability was observed for ofloxacin elimination parameters (CI/F, renal CI(R)/F) and half-life. In contrast, within-group and between-group differences in the volume of distribution adjusted for weight were not significant (group A: 1.22 +/- 0.44 l.kg; group B: 1.49 +/- 0.53 l.kg), but these values were approximately half those observed in the young adult. Plasmatic [CI/F] and renal clearance [CI(R)/F] of ofloxacin were correlated with creatinine clearance in both groups and in the overall population studied. Then the overall population was classified in terms of creatinine clearance [group 1: greater than 50 ml/min; group 2: less than or equal to 50 (minimum 20) ml/min]. The pharmacokinetics of ofloxacin in the elderly are characterized by a decrease in the volume of distribution and in plasmatic and renal clearances.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:1523592pubmed:languagefrelld:pubmed
pubmed-article:1523592pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1523592pubmed:citationSubsetIMlld:pubmed
pubmed-article:1523592pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1523592pubmed:statusMEDLINElld:pubmed
pubmed-article:1523592pubmed:issn0040-5957lld:pubmed
pubmed-article:1523592pubmed:authorpubmed-author:ChauvinMMlld:pubmed
pubmed-article:1523592pubmed:authorpubmed-author:VeyssierPPlld:pubmed
pubmed-article:1523592pubmed:authorpubmed-author:FarinottiRRlld:pubmed
pubmed-article:1523592pubmed:authorpubmed-author:DarchisJ PJPlld:pubmed
pubmed-article:1523592pubmed:authorpubmed-author:BardinCClld:pubmed
pubmed-article:1523592pubmed:authorpubmed-author:ClavierMMlld:pubmed
pubmed-article:1523592pubmed:issnTypePrintlld:pubmed
pubmed-article:1523592pubmed:volume47lld:pubmed
pubmed-article:1523592pubmed:ownerNLMlld:pubmed
pubmed-article:1523592pubmed:authorsCompleteYlld:pubmed
pubmed-article:1523592pubmed:pagination35-9lld:pubmed
pubmed-article:1523592pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1523592pubmed:meshHeadingpubmed-meshheading:1523592-...lld:pubmed
pubmed-article:1523592pubmed:meshHeadingpubmed-meshheading:1523592-...lld:pubmed
pubmed-article:1523592pubmed:meshHeadingpubmed-meshheading:1523592-...lld:pubmed
pubmed-article:1523592pubmed:meshHeadingpubmed-meshheading:1523592-...lld:pubmed
pubmed-article:1523592pubmed:meshHeadingpubmed-meshheading:1523592-...lld:pubmed
pubmed-article:1523592pubmed:meshHeadingpubmed-meshheading:1523592-...lld:pubmed
pubmed-article:1523592pubmed:meshHeadingpubmed-meshheading:1523592-...lld:pubmed
pubmed-article:1523592pubmed:meshHeadingpubmed-meshheading:1523592-...lld:pubmed
pubmed-article:1523592pubmed:articleTitle[Pharmacokinetics of ofloxacin administered orally in elderly subjects with bronchial or urinary tract infections].lld:pubmed
pubmed-article:1523592pubmed:affiliationService de Pharmacie Clinique et des Biomatériaux, Groupe Hospitalier X. Bichat-Cl. Bernard, Paris.lld:pubmed
pubmed-article:1523592pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1523592pubmed:publicationTypeEnglish Abstractlld:pubmed